

Isolation and Structure Elucidation of Two New Alkaloids, Pandamarilactonine-C and -D, from *Pandanus amaryllifolius* and Revision of Relative Stereochemistry of Pandamarilactonine-A and -B by Total Synthesis

Hiromitsu TAKAYAMA,^{*,a} Tomotake ICHIKAWA,^a
Mariko KITAJIMA,^a Maribel G. NONATO,^b and
Norio AIMI^a

^a Graduate School of Pharmaceutical Sciences, Chiba University; 1–33 Yayoi-cho, Inage-ku, Chiba 263–8522, Japan; and ^b Research Center for the Natural Sciences, University of Santo Tomas; Espana, Manila 1008, Philippines.

Received July 8, 2002; accepted July 30, 2002; published online July 31, 2002

Two new pyrrolidine alkaloids, pandamarilactonine-C and -D, were isolated from *Pandanus amaryllifolius*. Based on the total synthesis of pandamarilactonine-C and its related alkaloid, pandamarilactonine-A, the relative stereochemistry of pandamarilactonine-A and -B, which was previously proposed by spectroscopic analysis, was revised.

Key words pyrrolidine alkaloid; *Pandanus*; pandamarilactonine; total synthesis; structure elucidation; structure revision


The genus *Pandanus* (Pandanaceae) comprises approximately 600 species that are widely distributed in tropical and subtropical regions. Several *Pandanus* species are used as a remedy for toothache and rheumatism, and as diuretic, cardiotonic, etc.¹⁾ In a recent pharmacological screening, the hypoglycemic effect of an extract of *P. odoratus* was noted.^{2–4)} In our continuing search for structurally unique and biologically active *Pandanus* alkaloids, new pyrrolidine alkaloids were found in *P. amaryllifolius* ROXB.^{5–7)} Further investigation of the minor constituents in the fresh leaves of this plant resulted in the isolation of two new alkaloids, pandamarilactonine-C and -D (**1**, **2**). In this communication, we describe the structure elucidation of these alkaloids as well as the total synthesis of pandamarilactonine-C (**1**) and its related alkaloid, pandamarilactonine-A (**3**), which resulted in the revision of the relative stereochemistry of pandamarilactonine-A and -B (**3**, **4**), which was previously proposed based on the results of spectroscopic analysis.

The crude alkaloid fraction (1.10 g), which was obtained from young leaves of *P. amaryllifolius*,⁵⁾ was initially separated by SiO₂ column chromatography using MeOH/CHCl₃ gradient, and then the 2–5% MeOH/CHCl₃ eluate was subjected to SiO₂ medium pressure liquid chromatography using 2% EtOH/CHCl₃ to give 20 mg of pandamarilactonine-C and 4 mg of pandamarilactonine-D.


The two new compounds, pandamarilactonine-C (**1**)⁸⁾ and pandamarilactonine-D (**2**),⁹⁾ gave respectively *m/z* 318.1691 [M+H]⁺ and *m/z* 318.1704 [M+H]⁺ by high-resolution FAB-MS, which established the molecular formulas of the two compounds as C₁₈H₂₃NO₄, and indicated that these are

isomers of coexisting alkaloids, pandamarilactonine-A and B.⁵⁾ The UV, ¹H- and ¹³C-NMR spectra of pandamarilactonine-C and -D were very similar to those of pandamarilactonine-A and B, which comprised γ -butylidene- α -methyl α,β -unsaturated γ -lactone and pyrrolidinyl α,β -unsaturated γ -lactone residues, indicating that these four alkaloids are stereoisomers. Unambiguous assignment of all the carbons and protons in **1**⁸⁾ and **2**⁹⁾ was realized using ¹H–¹H correlated spectroscopy (COSY), heteronuclear multiple quantum coherence (HMQC), and heteronuclear multiple bond correlation (HMBC) spectra. Comparing the ¹³C-NMR data of **1** and **2** with those of **3** and **4**,⁵⁾ a significant difference was observed in the chemical shifts at the C-4 position. The signals of **1** (δ 130.3) and **2** (δ 133.9) appeared in the higher field than those of **3** (δ 137.7) and **4** (δ 137.7), which can be reasonably interpreted in terms of the γ -gauche effect due to the *E* configuration in the γ -alkylidene- γ -lactone moiety of both **1** and **2**. Differential nuclear Overhauser effect (NOE) experiments on **1** and **2**, *i.e.*, observation of a clear peak enhancement from H-4 to H-7, also demonstrated the *E* configuration of the γ -alkylidenebutenolide moiety. All of the above findings enabled us to elucidate the molecular structures of the new alkaloids (**1**, **2**) except for the stereochemistry of the vicinal asymmetric center at the C-14 and C-15 positions.

To confirm the structures and the relative stereochemistry at the C-14 and C-15 positions in the new alkaloids, we attempted the total synthesis of pandamarilactonines. The lower part of the alkaloids, *i.e.*, the pyrrolidinyl α,β -unsaturated γ -lactone residue, was synthesized according to the procedure of Martin *et al.*¹⁰⁾ as follows. Compound (**7**), whose stereochemistry at the vicinal positions was established to be *threo* by X-ray analysis,¹⁰⁾ was prepared by vinylogous Mannich coupling reaction of **5** and **6**. The protecting group on the nitrogen in **7** was removed by treatment with TMSI in CH₃CN to give **8** in 94% yield. The iodide (**13**) corresponding to the upper part of pandamarilactonines was prepared by a three-step operation: i) condensation of the alde-



Pandamarilactonine-C (**1**) (6*E*, *threo*) Pandamarilactonine-D (**2**) (6*E*, *erythro*)



Pandamarilactonine-A (**3**) (6*Z*, *threo*) Pandamarilactonine-B (**4**) (6*Z*, *erythro*)

* To whom correspondence should be addressed. e-mail: htakayam@p.chiba-u.ac.jp




Chart 1. Total Synthesis of (±)-Pandamarilactonine-A and -C

hyde (**9**) with the siloxyfuran (**10**) in the presence of $\text{BF}_3 \cdot \text{Et}_2\text{O}$; ii) dehydration of the resultant aldol adduct (**11**) with trifluoromethanesulfonic anhydride and pyridine¹¹ (48% overall yield); and iii) halogen exchange of (**12**) with NaI in acetone (47% yield). The thus-obtained C9 unit (**13**) consisted of *Z* and *E* isomers in the ratio of 4.6:1, and was then condensed with secondary amine (**8**) in acetonitrile in the presence of K_2CO_3 to give two pandamarilactonines in 33% and 7% yields, both of which possessed the *threo* form at the C-14 and C-15 positions. The major synthetic product having the *Z* configuration was completely identical with natural pandamarilactonine-A and the minor one having the *E* configuration was identical with natural pandamarilactonine-C, respectively, by direct comparison of their chromatographic behavior, as well as their mass, and ^1H - and ^{13}C -NMR spectra. Based on the results of this synthetic study, the structures of pandamarilactonine-C, -D, -A, and -B were unambiguously established to be formulas **1** to **4**, respectively. The stereochemistry at the vicinal centers in pandamarilactonine-A and -B was analyzed by spectroscopic methods and the structures having the *erythro*-form for pandamarilactonine-A and the *threo*-form for B have been proposed.⁵ However, they should be revised as above.

Acknowledgments This work was supported in part by a Grant-in-Aid (No. 14370718) for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan.

References and Notes

- 1) Tan M., "Philippine Medicinal Plants in Common Use: Their Phytochemistry and Pharmacology," AKAP, Quezon City, 1980.
- 2) Peungvicha P., Thirawarapan S. S., Watanabe H., *Biol. Pharm. Bull.*, **19**, 364—366 (1996).
- 3) Peungvicha P., Thirawarapan S. S., Watanabe H., *Jpn. J. Pharmacol.*, **78**, 395—398 (1998).
- 4) Peungvicha P., Temsiririrkkul R., Prasain J. K., Tezuka Y., Kadota S., Thirawarapan S. S., Watanabe H., *J. Ethnopharmacol.*, **62**, 79—84 (1998).
- 5) Takayama H., Ichikawa T., Kuwajima T., Kitajima M., Seki H., Aimi N., Nonato M. G., *J. Am. Chem. Soc.*, **122**, 8635—8639 (2000).
- 6) Takayama H., Ichikawa T., Kitajima M., Aimi N., Lopez D., Nonato M. G., *Tetrahedron Lett.*, **42**, 2995—2996 (2001).
- 7) Takayama H., Ichikawa T., Kitajima M., Nonato M. G., Aimi N., *J. Nat. Prod.*, **64**, 1224—1225 (2001).
- 8) Pandamarilactonine-C (**1**): An amorphous powder, $[\alpha]_D^{25} +26.2^\circ$ ($c=0.99$, CHCl_3), UV (MeOH) λ_{max} nm (log ϵ): 275 (4.23), 220 (sh), 201 (3.67). IR (neat) ν_{max} cm^{-1} : 1758 (lactone). FAB-MS (NBA) m/z : 318 $[\text{M}+\text{H}]^+$. HR-FAB-MS (NBA): Calcd for $\text{C}_{18}\text{H}_{23}\text{NO}_4$: 318.1704, Found 318.1691. ^1H -NMR (500 MHz, CDCl_3) δ : 7.31 (1H, dd, $J=0.9, 1.5$ Hz, H-4), 7.04 (1H, d-like, $J=1.5$ Hz, H-16), 5.64 (1H, dd, $J=8.2, 8.5$ Hz, H-6), 4.80 (1H, ddd, $J=1.8, 1.8, 5.5$ Hz, H-15), 3.12 (1H, dd-like, $J=6.7, 7.3$ Hz, H-11), 2.91 (1H, ddd, $J=7.9, 8.2, 11.9$ Hz, H-9), 2.78 (1H, m, H-14), 2.45 (1H, ddd, $J=5.8, 7.0, 11.9$ Hz, H-9), 2.35 (1H, ddd, $J=7.0, 8.2, 14.7$ Hz, H-7), 2.25 (2H, m, H-7 and H-11), 2.02 (3H, d, $J=0.9$ Hz, H_3 -21), 1.94 (3H, d-like, $J=1.8$ Hz, H_3 -20), 1.71—1.82 (2H, m, H-12, H-13), 1.62—1.68 (3H, m, H-2, H-8, H-13), 1.45 (1H, m, H-12). ^{13}C -NMR (125 MHz, CDCl_3) δ : 174.2 (C-18), 171.0 (C-2), 148.7 (C-5), 146.7 (C-16), 131.3 (C-17), 130.3 (C-4), 129.1 (C-3), 113.4 (C-6), 83.8 (C-15), 65.6 (C-14), 55.2 (C-9), 54.2 (C-11), 29.1 (C-8), 26.1 (C-12), 24.2 (C-7), 23.8 (C-13), 10.8 (C-20, C-21).
- 9) Pandamarilactonine-D (**2**): An amorphous powder, $[\alpha]_D^{25} 0^\circ$ ($c=0.21$, CHCl_3), UV (MeOH) λ_{max} nm (log ϵ): 276 (4.38), 234 (sh), 203 (4.30). IR (neat) ν_{max} cm^{-1} : 1760 (lactone). FAB-MS (NBA) m/z : 318 $[\text{M}+\text{H}]^+$. HR-FAB-MS (NBA): Calcd for $\text{C}_{18}\text{H}_{23}\text{NO}_4$: 318.1704, Found 318.1704. ^1H -NMR (500 MHz, CDCl_3) δ : 7.35 (1H, m, H-4), 6.99 (1H, dd, $J=1.5, 1.7$ Hz, H-16), 5.60 (1H, dd, $J=8.3, 8.8$ Hz, H-6), 4.74 (1H, m, H-15), 3.08 (1H, m, H-11), 2.77 (1H, m, H-9), 2.72 (1H, m, H-14), 2.42 (1H, m, H-9), 2.29 (2H, m, H_2 -7), 2.25 (1H, m, H-11), 2.01 (3H, m, H_3 -21), 1.94 (3H, dd-like, $J=1.5, 2.0$ Hz, H_3 -20), 1.78—1.92 (4H, m, H_2 -12, H_2 -13), 1.63 (2H, m, H_2 -8). ^{13}C -NMR (125 MHz, CDCl_3) δ : 174.3 (C-18), 171.0 (C-2), 149.0 (C-5), 147.1 (C-16), 131.0 (C-17), 133.9 (C-4), 130.3 (C-3), 113.3 (C-6), 83.0 (C-15), 65.9 (C-14), 55.1 (C-9), 54.0 (C-11), 28.7 (C-8), 26.3 (C-12), 24.0 (C-7), 23.9 (C-13), 10.8 (C-20), 10.7 (C-21).
- 10) Martin S. F., Barr K. J., Smith D. W., Bur S. K., *J. Am. Chem. Soc.*, **121**, 6990—6997 (1999).
- 11) Bruckner R., *Chem. Commun.*, **2001**, 141—152 (2001), and references cited therein.
- 12) Note added in proof: After submission of the paper, a total synthesis of pandamarilactonine-A and -B was published. Busque F., March P., Figueredo M., Font J., Sanfeliu E., *Tetrahedron Lett.*, **43**, 5583—5585 (2002).